Bases Neurobiológicas y Psicológicas de los Trastornos Mentales. Trastornos del Neurodesarrollo

Cleynen, I; Engchuan, W; Hestand, MS; Heung, T; Holleman, AM; Johnston, HR; Monfeuga, T; McDonald-McGinn, DM; Gur, RE; Morrow, BE; Swillen, A; Vorstman, JAS; Bearden, CE; Chow, EWC; van den Bree, M; Emanuel, BS; Vermeesch, JR; Warren, ST; Owen, MJ; Chopra, P; Cutler, DJ; Duncan, R; Kotlar, AV; Mulle, JG; Voss, AJ; Zwick, ME; Diacou, A; Golden, A; Guo, TW; Lin, JR; Wang, T; Zhang, ZD; Zhao, YJ; Marshall, C; Merico, D; Jin, A; Lilley, B; Salmons, HI; Tran, O; Holmans, P; Pardinas, A; Walters, JTR; Demaerel, W; Boot, E; Butcher, NJ; Costain, GA; Lowther, C; Evers, R; van Amelsvoort, TAMJ; van Duin, E; Vingerhoets, C; Breckpot, J; Devriendt, K; Vergaelen, E; Vogels, A; Crowley, TB; McGinn, DE; Moss, EM; Sharkus, RJ; Unolt, M; Zackai, EH; Calkins, ME; Gallagher, RS; Gur, RC; Tang, SX; Fritsch, R; Ornstein, C; Repetto, GM; Breetvelt, E; Duijff, SN; Fiksinski, A; Moss, H; Niarchou, M; Murphy, KC; Prasad, SE; Daly, EM; Gudbrandsen, M; Murphy, CM; Murphy, DG; Buzzanca, A; Di Fabio, F; Digilio, MC; Pontillo, M; Marino, B; Vicari, S; Coleman, K; Cubells, JF; Ousley, OY; Carmel, M; Gothelf, D; Mekori-Domachevsky, E; Michaelovsky, E; Weinberger, R; Weizman, A; Kushan, L; Jalbrzikowski, M; Armando, M; Eliez, S; Sandini, C; Schneider, M; Bena, FS; Antshel, KM; Fremont, W; Kates, WR; Belzeaux, R; Busa, T; Philip, N; Campbell, LE; McCabe, KL; Hooper, SR; Schoch, K; Shashi, V; Simon, TJ; Tassone, F; Arango, C; Fraguas, D; Garcia-Minaur, S; Morey-Canyelles, J; Rosell, J; Suner, DH; Raventos-Simic, J; Epstein, MP; Williams, NM; Bassett, AS; Int 22q112DS Brain Behav Consortiu.

Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion

MOLECULAR PSYCHIATRY. 2021; 26(8): 4496-4510 Nº de citas: 88 [doi:10.1038/s41380-020-0654-3]

Balhara, YPS; Szerman, N; Singh, S; Raga, JM; Salom, C; Peris, L; Ganesh, R.

Treatment Needs and Service Delivery for Patients with Dual Disorders During the COVID-19 Pandemic: Findings From the WADD Survey

JOURNAL OF DUAL DIAGNOSIS. 2021; 17(3): 248-256 Nº de citas: 4 [doi:10.1080/15504263.2021.1940413]

Bernardo M; Amoretti S; Cuesta MJ; Parellada M; Mezquida G; 2EPs Group; González-Pinto A; Bergé D; Lobo A; Aguilar EJ; Usall J; Corripio I; Bobes J; Rodríguez-Jiménez R; Sarró S; Contreras F; Ibáñez Á; Gutiérrez M; Micó JA.

The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design.

Revista De Psiquiatria Y Salud Mental. 2021; 14(3): 164-176 Nº de citas: 3 [doi:10.1016/j.rpsmen.2021.08.001]

Penuelas-Calvo, I; Palomar-Ciria, N; Porras-Segovia, A; Miguelez-Fernandez, C; Baltasar-Tello, I; Perez-Colmenero, S; Delgado-Gomez, D; Carballo, JJ; Baca-Garcia, E.

Impact of ADHD symptoms on family functioning, family burden and parents' quality of life in a hospital area in Spain

EUROPEAN JOURNAL OF PSYCHIATRY. 2021; 35(3): 166-172 Nº de citas: 7 [doi:10.1016/j.ejpsy.2020.10.003]

Bernardo, M; Amoretti, S; Cuesta, MJ; Parellada, M; Mezquida, G; 2EPs Grp.

The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design

SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTH. 2021; 14(3): 164-176 Nº de citas: 10 [doi:10.1016/j.rpsm.2020.07.004]

Jongsma, HE; Gayer-Anderson, C; Tarricone, I; Velthorst, E; van der Ven, E; Quattrone, D; di Forti, M; Menezes, PR; Del-Ben, CM; Arango, C; Lasalvia, A; Berardi, D; La Cascia, C; Bobes, J; Bernardo, M; Sanjuaan, J; Santos, JL; Arrojo, M; de Haan, L; Tortelli, A; Szoke, A; Murray, RM; Rutten, BP; van Os, J; Morgan, C; Jones, PB; Kirkbride, JB; EU-GEI WP2 Grp.

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study

PSYCHOLOGICAL MEDICINE. 2021; 51(9): 1536-1548 Nº de citas: 70 [doi:10.1017/S003329172000029X]

Siafis, S; Rodolico, A; Ciray, O; Murphy, DG; Parellada, M; Arango, C; Leucht, S.

Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder

Brain Sciences. 2021; 11(7): Nº de citas: 4 [doi:10.3390/brainsci11070908]

Pretzsch, CM; Floris, DL; Voinescu, B; Elsahib, M; Mendez, MA; Wichers, R; Ajram, L; Ivin, G; Heasman, M; Pretzsch, E; Williams, S; Murphy, DGM; Daly, E; McAlonan, GM.

Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin

Molecular Autism. 2021; 12(1): 49-49 Nº de citas: 12 [doi:10.1186/s13229-021-00454-6]

Diaz-Caneja, CM; State, MW; Hagerman, RJ; Jacquemont, S; Marin, O; Bagni, C; Umbricht, D; Simonoff, E; de Andres-Trelles, F; Kaale, A; Pandina, G; Gomez-Mancilla, B; Wang, P; Cusak, J; Siafis, S; Leucht, S; Parellada, M; Loth, E; Charman, T; Buitelaar, JK; Murphy, D; Arango, C.

A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders

EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021; 48: 49-88 Nº de citas: 36 [doi:10.1016/j.euroneuro.2021.02.020]

McCracken, JT; Anagnostou, E; Arango, C; Dawson, G; Farchione, T; Mantua, V; McPartland, J; Murphy, D; Pandina, G; Veenstra-VanderWeele, J; ISCTM ECNP ASD Working Grp.

Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions

EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021; 48: 3-31 Nº de citas: 48 [doi:10.1016/j.euroneuro.2021.05.010]

Szerman, N; Arias, F; Algorta, J; Basurte, I; Vega, P; Roncero, C; Martinez-Raga, J; Grau-Lopez, L.

Effectiveness of tianeptine in patients with major depressive disorder and substance use disorder

ACTAS ESPANOLAS DE PSIQUIATRIA. 2021; 49(4): 135-144 Nº de citas: 1

Noel, GJ; Nelson, RM; Bucci-Rechtweg, C; Portman, R; Miller, T; Green, DJ; Snyder, D; Moreno, C; Hovinga, C; Connor, E.

Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children's Pediatric Innovation Research Forum

Therapeutic Innovation & Regulatory Science. 2021; 55(4): 773-778 Nº de citas: 9 [doi:10.1007/s43441-021-00283-y]

Kuzman, MR; Vahip, S; Fiorillo, A; Beezhold, J; da Costa, MP; Skugarevsky, O; Dom, G; Pajevic, I; Peles, AM; Mohr, P; Kleinberg, A; Chkonia, E; Balazs, J; Flannery, W; Mazaliauskiene, R; Chihai, J; Samochowiec, J; Cozman, D; Mihajlovic, G; Izakova, L; Arango, C; Goorwod, P.

Mental health services during the first wave of the COVID-19 pandemic in Europe: Results from the EPA Ambassadors Survey and implications for clinical practice

EUROPEAN PSYCHIATRY. 2021; 64(1): Nº de citas: 40 [doi:10.1192/j.eurpsy.2021.2215]

de Pablo, GS; Besana, F; Arienti, V; Catalan, A; Vaquerizo-Serrano, J; Cabras, A; Pereira, J; Soardo, L; Coronelli, F; Kaur, S; da Silva, J; Oliver, D; Petros, N; Moreno, C; Gonzalez-Pinto, A; Diaz-Caneja, CM; Shin, JI; Politi, P; Solmi, M; Borgatti, R; Mensi, MM; Arango, C; Correll, CU; McGuire, P; Fusar-Poli, P.

Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis

Eclinicalmedicine. 2021; 36: 100909-100909 Nº de citas: 42 [doi:10.1016/j.eclinm.2021.100909]

Amoretti, S; Verdolini, N; Mezquida, G; Rabelo-da-Ponte, FD; Cuesta, MJ; Pina-Camacho, L; Gomez-Ramiro, M; De-la-Camara, C; Gonzalez-Pinto, A; Diaz-Caneja, CM; Corripio, I; Vieta, E; de la Serna, E; Mane, A; Sole, B; Carvalho, AF; Serra, M; Bernardo, M.

Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique

EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021; 47: 112-129 Nº de citas: 12 [doi:10.1016/j.euroneuro.2021.01.095]

Amoretti, S; Mezquida, G; Rosa, AR; Bioque, M; Cuesta, MJ; Pina-Camacho, L; Garcia-Rizo, C; Barcones, F; Gonzalez-Pinto, A; Merchan-Naranjo, J; Corripio, I; Vieta, E; Baeza, I; Cortizo, R; Bonnin, CM; Torrent, C; Bernardo, M; PEPs Grp.

The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds

EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021; 47: 98-111 Nº de citas: 25 [doi:10.1016/j.euroneuro.2021.02.007]

Quattrone, D; Ferraro, L; Tripoli, G; La Cascia, C; Quigley, H; Quattrone, A; Jongsma, HE; Del Peschio, S; Gatto, G; Gayer-Anderson, C; Jones, PB; Kirkbride, JB; La Barbera, D; Tarricone, I; Berardi, D; Tosato, S; Lasalvia, A; Szoke, A; Arango, C; Bernardo, M; Bobes, J; Del Ben, CM; Menezes, PR; Llorca, PM; Santos, JL; Sanjuan, J; Tortelli, A; Velthorst, E; de Haan, L; Rutten, BPF; Lynskey, MT; Freeman, TP; Sham, PC; Cardno, AG; Vassos, E; van Os, J; Morgan, C; Reininghaus, U; Lewis, CM; Murray, RM; Di Forti, M; EU-GEI grp.

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study

PSYCHOLOGICAL MEDICINE. 2021; 51(8): 1329-1337 Nº de citas: 53 [doi:10.1017/S0033291720000082]

Molina-Garcia, M; Fraguas, D; del Rey-Mejias, A; Mezquida, G; Sanchez-Torres, AM; Amoretti, S; Lobo, A; Gonzalez-Pinto, A; Andreu-Bernabeu, A; Corripio, I; Vieta, E; Baeza, I; Mane, A; Cuesta, M; de la Serna, E; Paya, B; Zorrilla, I; Arango, C; Bernardo, M; Rapado-Castro, M; Parellada, M; PEPs Grp.

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

Journal of Clinical Medicine. 2021; 10(11): Nº de citas: 9 [doi:10.3390/jcm10112474]